Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Immune Checkpoint Inhibitor Combined With Pemetrexed Intrathecal Injection for Leptomeningeal Metastasis From Solid Tumors: a Phase I/II Study

NCT06462222 is registered in ClinicalTrials.gov with Guangzhou Medical University as lead sponsor.

NCT NCT06462222
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06462222 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Immune Checkpoint Inhibitor Combined With Pemetrexed Intrathecal Injection for Leptomeningeal Metastasis From Solid Tumors: a Phase I/II Study
Lead sponsor
Guangzhou Medical University
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
June 30, 2024
Completion date
September 30, 2026
Enrollment
45 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

leptomeningeal metastasis